No.movember.co

RECIPIENT & INSTITUTION
Identifying novel mechanisms of androgen-mediated growth control as new targets for intervention and prognostic biomarkers in prostate cancer (PG12-34) Targeting ABC transporter autocrine loop in prostate cancer (PG12-23) Enhancement of targeted radiotherapy for prostate cancer using PSMA-seeking agents in combination with radiosensitisers (PG12-12) Investigating the regulation and effects on androgen receptor expression using culture models of castration resistant prostate cancer that induce embryonic stem Advanced prostate cancer: does targeting hypoxic cel s block malignant Quantitative shear wave elastosonography in the detection and characterisation Evaluating synergy between deregulation of the PI3-kinase, Wnt and Ras pathways in prostate neoplasia (PG12-16) Using circulating plasma DNA as a multi-purpose biomarker to identify aggressive prostate cancer and mechanisms of drug resistance (PG12-49) Development of a first-in-class preclinical drug candidate for the treatment of castrate-resistant prostate cancer (PG12-27) Developing a new targeted therapy for treatment of metastatic prostate cancer: synthesis and preclinical validation of sphingosine kinase inhibitor-docetaxel Targeting the tumour-initiating population in prostate cancer Imaging avb3 integrin expression in skeletal metastases from prostate cancer with 99mTc-maraciclatide single photon emission computed tomography (SPECT): staging and therapy monitoring (PA12-04) Development of a novel cytotopic immunotherapeutic cocktail for targeted treatment of advanced prostate cancer (PA12-01) Role of Receptor Activity Modifying Protein-3 in regulation of lysyl oxidase-2 Prostate cancer immunotherapy using genetical y targeted T-cel s, guided by a stromal-specific immunocytokine (PA12-06) Prostate cancer response assessment and treatment stratification through circulating free tumour DNA detection (PA12-15) Therapeutic inhibition of the Histone Demethylase LSD1 to attenuate androgen receptor signal ing in prostate cancer (PG12-03) The use of a novel technology platform to create a DNA vaccine for Role of stroma microenvironments in prostate cancer cell migration Development of a transcriptional repressor based approach for the treatment Aldehyde dehydrogenases in prostate cancer (S12-027) RECIPIENT & INSTITUTION
The FAS/AMPK axis as a determinant of prostate cancer progression (S12-008) Identification and validation of novel therapeutic targets in prostate cancer by investigating the cell kil ing mechanisms of the oncolytic adenovirus Ad in combination with cytotoxic drugs (S12-021) Characterising novel phosphatase enzymes important in regulating androgen receptor function in the progression of castrate Influence of stage and therapy on the NKG2D axis in prostate cancer Development of tumour-selective therapeutics for advanced Synergistic interaction between Sprouty2 loss and PI3K/AKT activation Beatson Institute, University of Glasgow The role of IKKa and IKKb in prostate cancer progression A new approach to evaluating prostate cancer diagnostic markers in men with a raised PSA undergoing template mapping biopsy Improving Prostate Cancer Diagnosis and Monitoring using Development of dual β3 integrin antagonists as a novel anti-metastatic therapeutic for castration-resistant prostate cancer The role of autophagy in the initiation, progression and recurrence Targeting AMACR to treat castrate-resistant prostate cancer Optimal radiation targeting of PTEN deficiency in castrate resistant prostate cancer in combination with modulators of DNA damage The androgen receptor amino-terminal domain: a novel drug target for the treatment of castrate resistant prostate cancer Development and evaluation of a guided self-help intervention to al eviate hormone treatment side effects (hot flushes and night sweats) A pilot randomized controlled trial of a nurse-led psycho-educational intervention delivered in primary care to prostate cancer survivors Role of the endogenous signal ing regulator Similar Expression to FGF (Sef) in growth factor signal ing in prostate cancer Mouse modeling of prostate cancer through TMP-ETS family The role of ubiquitin in androgen receptor function in prostate cancer A novel chemoprotective role for vitamin D in prostate cancer Exploiting defects in DNA repair for treatment of prostate cancer RECIPIENT & INSTITUTION
A Phase Ib/II trial of Prostate Radiotherapy in Conjunction with Carbogen Living with and beyond Prostate Cancer: Does more investigation result in better health? A study of the impact on men of increased and variable investigation and treatment of prostate cancer in the Island of Ireland The public face of prostate cancer in the UK A new approach to delivery of super-potent drugs to prostate tumours Trial of devices for intractable urinary incontinence fol owing prostate Identifying mechanisms of resistance to specific CYP17 inhibition with Novel proteomic approach combined with an RNAi screen to identify Sphingosine kinase-1 signal ing during prostate cancer cel motility, Understanding prostate tumour response to bicalutamide can lead DNA damage response in prostate cancer stem cel s A mechanism-based system of classification for human prostate cancer Analysis of stromal signaling pathways in human prostate cancer initiation The use of nitric oxide in combination with radiotherapy as a new treatment for prostate cancer found under low oxygen conditions

Source: http://no.movember.co/uploads/files/2013/Report%20Cards/UK_PC_Funded_FINAL.pdf